AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn’s Disease October 1, 2026 8:30 AM EDT
Company Participants
Tim Knotnerus – CEO & Executive Director
Philippe Wiesel – Chief Medical Officer
Florian Rieder
Conference Call Participants
Judah Frommer – Morgan Stanley, Research Division
Anupam Rama – JPMorgan Chase & Co, Research Division
Thomas Smith – Leerink Partners LLC, Research Division
Shannon Duffy
Ioannis Souroutzidis – Cantor Fitzgerald & Co., Research Division
Luis Santos – H.C. Wainwright & Co, LLC, Research Division
Sushila Hernandez – Kempen & Co. N.V., Research Division
William Wood – B. Riley Securities, Inc., Research Division
Presentation
Operator
Good morning, everyone, and welcome to the AgomAb Therapeutics Virtual Management and KOL event. [Operator Instructions] As a reminder, this webinar is being recorded, and a replay will be made available on the AgomAb website following the conclusion of the event.
Before we begin, we would like to remind everyone that today’s presentation contains forward-looking statements. These statements are subject to risks and uncertainties that may cause actual results to differ materially.
Please refer to AgomAb’s SEC filings for a discussion of these risks. I’d now like to turn the call over to Tim Knotnerus, Chief Executive Officer at AgomAb Therapeutics. Please go ahead, Tim.
Tim Knotnerus
CEO & Executive Director
Thank you so much, Sarah, and thank you all for joining today’s webcast to discuss the open-label extension results of the Phase IIa STENOVA study in patients with Fibrostenosing Crohn’s disease.
Let me introduce our speakers for today. Very glad we are joined by Dr. Rieder from the Cleveland Clinic, who is also Chair of the STAR Consortium.
On the company side, I’m joined by Chief Medical Officer, Philippe Wiesel; and Chief Financial Officer, Pierre Kemula. I’m Tim Knotnerus, and thank you so much for joining today.
Today, I
